Late sodium current Inhibitors
1 drugsAbout Late sodium current
The late sodium current (INaL) is a sustained inward sodium current during the cardiac action potential's plateau phase. Increased INaL can disrupt cellular electrophysiology. It has emerged as a drug target where cellular excitability plays a key role.
INaL modulation aims to restore normal cellular function and alleviate disease symptoms. Currently, there is no genetic evidence directly linking variations in genes encoding INaL components to specific diseases.
Ranolazine is the only FDA-approved drug modulating INaL. It is a small molecule approved in 2013 by I3 PHARMS for one indication in the 'other' therapeutic area.
Top Late sodium current Drugs
I3 PHARMS is the only company with an approved drug targeting INaL.
The market is highly concentrated, suggesting high barriers to entry or limited commercial interest.
Late sodium current Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Late sodium current, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
Late sodium current Clinical Trials 56 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Late sodium current. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 | 100% |
| Phase 2 | 22 | 12 | 7 | 3 | 63% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 16 | 10 | 6 | 0 | 63% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Late sodium current Drug Approval Timeline (2013 - 2013)
The first and only drug, Ranolazine, was approved in 2013.
The approval timeline suggests potential saturation or lack of recent innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Late sodium current. A trial counts if an approved drug acting on Late sodium current is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.